Mabpharm (SEHK:2181) Profit Growth Meets Cash Conversion And Debt Questions

Mabpharm stock closed flat at HK$0.435 going into these half year numbers, even as traders weighed a biotech now trading on an 18x P/E and freshly profitable over the last twelve months. The headline is not the share price. It is that H1 2026 revenue reached ¥397.9m with basic earnings per share of ¥0.01, keeping the profitability story alive but raising questions about how much of that profit truly converts to cash.

For long term holders, the real debate now shifts to the quality of those earnings and how the company’s debt load shapes the next few years.

Is Mabpharm’s 18x P/E a fair price for newly profitable earnings built on heavy non cash items, or is the stock quietly misaligned with peers? Compare how the current multiples line up in the full valuation analysis for Mabpharm

H1 2026 Earnings Summary

• Revenue H1 2026 vs. H1 2025: ¥397.941 million vs. ¥274.183 million (very large increase)
• Net Income H1 2026 vs. H1 2025: ¥31.36 million vs. ¥2.898 million (very large increase)
• Basic EPS H1 2026 vs. H1 2025: ¥0.01 per share vs. ¥0.000702 per share (very large increase)
• Trailing 12 Month Net Income to H1 2026 vs. TTM to H1 2025: ¥85.595 million vs. a loss of ¥27.48 million (swing from loss to profit)

Prefer clean charts to another dense block of earnings tables and footnotes? See Mabpharm’s full financial picture, including a clear view of its profitability trend and drivers, in the visual company report for Mabpharm.

Mabpharm earnings keep cautious optimism alive

The latest Mabpharm numbers give the bullish story more substance. Revenue of ¥397.941m for H1 2026 sits well above the prior ¥274.183m. This fits a narrative of a platform that is starting to scale commercially. Net income of ¥31.36m for the half and ¥85.595m over the last twelve months supports the idea that the business model can produce earnings, not just pipeline headlines. For a sector often defined by cash burn, a consistent profit print helps investors treat Mabpharm as more than a pure R&D option.

Profit quality and cash risks still matter

The bear case around Mabpharm does not disappear with one set of profitable numbers. Net income improved from ¥2.898m in H1 2025 to ¥31.36m in H1 2026 and the trailing twelve month swing from a ¥27.48m loss to an ¥85.595m profit is encouraging. However, it also raises questions about sustainability and cash conversion. Biopharma earnings can be sensitive to one off items and accounting choices. For investors focused on balance sheet strength, the next step is to see how much of this profit translates into recurring operating cash flow.

Scan Mabpharm’s non-cash earnings profile and debt burden to see if these profits mask deeper structural issues in our risk analysis for Mabpharm which shows 2 important warning signs.

Keep Your Edge With Simply Wall St

If Mabpharm’s shift to profitability and 18x P/E has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the story develops. Once you own it or any other stock, use the Portfolio Command Center to cut through noise and focus on the updates that matter for your holdings. For a broader view on sentiment and possible catalysts, tap into the Community and see how other investors are thinking about opportunities and risks. This way you can spot potential turning points early, stay ahead of key changes and keep your decisions grounded in clear data.

Seeking Fresh Alternatives Beyond Mabpharm

Markets move fast and attractive entry points can appear before headlines catch up. Scan fresh stock ideas that may be building breakout momentum while they are still relatively under the radar and consider them in a timely way.

• Identify companies with strong cash generation and resilient balance sheets before they attract more institutional attention by running the curated list of solid balance sheet and fundamentals stocks (426 results).
• Explore potential momentum in smaller AI stocks that are already generating profit by screening with the focused 73 profitable AI stocks that aren't just burning cash.
• Review opportunities related to potential infrastructure activity in power networks by checking the hand picked 38 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com